EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

Phase 1 study of the iodine absorption, safety, and tolerability of a 0.5% povidone‐iodine nasal spray (Nasodine)

Peter L Friedland iD, Thomas M Polasek, Duncan Topliss

International Forum of Allergy & Rhinology · 2024

DOI: 10.1002/alr.23389 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift International Forum of Allergy & Rhinology, 2024. Verfasst von Peter L Friedland und 2 weiteren Autor:innen. Beteiligte Einrichtung: Medical School, University of Western Australia, Perth, Western Australia, Australia. Hauptthemen laut MEDLINE: Anti-Infective Agents, Local, Iodine, Nasal Sprays, Povidone-Iodine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Firebrick Pharma Pty Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Key points PVP‐I is a widely used antiseptic but only recently proposed for intranasal use. The extent of iodine absorption from available PVP‐I nasal products is unknown. Iodine absorption from use of Nasodine (0.5% PVP‐I nasal spray) is not clinically significant.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Infective Agents, LocalIodineNasal SpraysPovidone-IodineAdultFemaleHumansMaleMiddle AgedYoung AdultAdministration, Intranasal

Stichwörter der Autor:innen

disease severityepithelial cellirrigationsmusocilliary clearancequality of lifetherapeutics

Substanzen

Anti-Infective Agents, LocalIodineNasal SpraysPovidone-Iodine

Autor:innen und Institutionen

  • Medical School, University of Western Australia, Perth, Western Australia, Australia.
  • Department Otolaryngology-Head and Neck Surgery, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.
  • Centre for Medicine Use and Safety, Monash University, Melbourne, Victoria, Australia.
  • CMAX Clinical Research, Adelaide, South Australia, Australia.
  • Department of Endocrinology and Diabetes, The Alfred Hospital, Melbourne, Victoria, Australia.
  • Department of Medicine, Monash University, Melbourne, Victoria, Australia.

ORCID-Profile: Peter L Friedland

Förderung

  • Firebrick Pharma Pty Ltd.

Zitieren

APA

Friedland, P. L., Polasek, T. M., & Topliss, D. (2024). Phase 1 study of the iodine absorption, safety, and tolerability of a 0.5% povidone‐iodine nasal spray (Nasodine). International Forum of Allergy & Rhinology. https://doi.org/10.1002/alr.23389

Vancouver

Friedland PL, Polasek TM, Topliss D. Phase 1 study of the iodine absorption, safety, and tolerability of a 0.5% povidone‐iodine nasal spray (Nasodine). International Forum of Allergy & Rhinology. 2024. doi:10.1002/alr.23389

BibTeX
@article{Friedland2024,
  author = {Friedland, Peter L and Polasek, Thomas M and Topliss, Duncan},
  title = {Phase 1 study of the iodine absorption, safety, and tolerability of a 0.5% povidone‐iodine nasal spray (Nasodine)},
  journal = {International Forum of Allergy & Rhinology},
  year = {2024},
  doi = {10.1002/alr.23389}
}
Kostenlos starten →